Journal of Oncology

Biomarkers for Breast Cancer Research, Diagnosis, and Treatment


Publishing date
01 Mar 2020
Status
Closed
Submission deadline
01 Nov 2019

Guest Editors

1Institute of Genetics and Molecular Medicine, Edinburgh, UK

2Queens Medical Research Institute, Edinburgh, UK

3Edinburgh Breast Unit, Western General Hospital, UK

This issue is now closed for submissions.
More articles will be published in the near future.

Biomarkers for Breast Cancer Research, Diagnosis, and Treatment

This issue is now closed for submissions.
More articles will be published in the near future.

Description

Biomarkers play an increasingly important role in cancer diagnosis and management. In advancement towards precision medicine, the field of cancer biomarker discovery has rapidly expanded over the last few decades. This has been developed by advances in technologies and approaches including next generation sequencing, mass spectrometry, circulating tumour cells, and cell-free DNA. The discovery and use of specific prognostic and predictive biomarkers have enabled the application of targeted precision therapies to specific molecular subgroups of patients likely to gain benefit. Indeed, the development in tandem of companion-diagnostics alongside new drugs is often essential to obtain licensing approval from regulatory bodies. Additionally, the use of biomarkers can allow for the identification of patients with a favorable prognosis who can safely be spared from unnecessary overtreatment.

Within breast cancer, recent biomarker discovery efforts have led to the identification and development of several prognostic and predictive biomarkers including multigene signatures. Some are now commercially available and approved for clinical use while others remain to be clinically validated. Despite these advances, there is still an important clinical need for the development and validation of novel biomarkers with greater sensitivity, specificity, and clinical utility.

This special issue aims to explore new and existing biomarker development and validation in breast cancer and also focus on new technologies and approaches. We encourage submissions of original research findings regarding new biomarkers for breast cancer and new approaches for their detection and validation. The markers may include, but are not limited to, genomic, transcriptomic, epigenetic, and proteomic. We also especially welcome review articles which describe the current state of biomarker development and clinical utility for breast cancer diagnosis and management.

Potential topics include but are not limited to the following:

  • Current and emerging biomarkers in breast cancer
  • Biomarkers for breast cancer diagnosis and treatment
  • Biomarkers for the following: patient suitability for treatment screening, prognosis, response to treatment, monitoring of disease progression, and relapse
  • Biomarkers for chemotherapy response
  • Biomarkers for endocrine therapy response
  • Biomarkers for radiotherapy response
  • Biomarkers for targeted therapies (including but not limited to HER2, CDK4/6, PARP, PD-1, and MTOR)
  • Biomarkers for novel therapeutics
  • Serum biomarkers
  • Genomic biomarkers (including but not limited to mutations, amplifications, and fusions)
  • Biomarker discovery
  • Novel methods/approaches for biomarker discovery
  • Novel methods for clinical detection of genomic biomarkers
  • Discovery and validation of secreted/serum biomarkers
  • Circulating tumour cells
  • Cell-free DNA

Articles

  • Special Issue
  • - Volume 2020
  • - Article ID 4181850
  • - Clinical Study

Effectiveness of a Global Multidisciplinary Supportive and Educational Intervention in Thermal Resort on Anthropometric and Biological Parameters, and the Disease-Free Survival after Breast Cancer Treatment Completion (PACThe)

Marie-Paule Vasson | Fabrice Kwiatkowski | ... | Yves-Jean Bignon
  • Special Issue
  • - Volume 2020
  • - Article ID 5169278
  • - Research Article

Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Liuwen Yu | Fangmeng Fu | ... | Chuan Wang
  • Special Issue
  • - Volume 2020
  • - Article ID 6375956
  • - Review Article

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer

Maria Gaibar | Laura Beltrán | ... | Apolonia Novillo
  • Special Issue
  • - Volume 2020
  • - Article ID 8132507
  • - Research Article

Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Gabriella Cirmena | Anna Garuti | ... | Gabriele Zoppoli
  • Special Issue
  • - Volume 2019
  • - Article ID 7386734
  • - Research Article

Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer

Young-Joon Kang | Han-Byoel Lee | ... | Wonshik Han
Journal of Oncology
 Journal metrics
Acceptance rate24%
Submission to final decision66 days
Acceptance to publication37 days
CiteScore1.400
Impact Factor2.206
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.